You are here: Industry Insights > Sun Pharma

News List

Sun's profit crushed as it pays $150M to settle Provigil pay-for-delay case fiercepharma
August 14, 2017
Sun Pharma saw its U.S. sales freefall 42% to $351 million in the last quarter as it was whiplashed by a host of issues.
FiercePharmaAsia—Sun’s quarterly loss, BeiGene’s $175M public offering, Biocon plant’s extensive pro fiercepharma
August 14, 2017
Sun Pharma took a hit with a 9.51 billion rupees antitrust settlement over Modafinil, a sleep disorder treatment.
Sun Pharma posts Q1FY18 results expressbpd
August 14, 2017
India sales is at Rs 1,761 crores, down by five per cent over Q1 last year
Sun Pharma & Samsung BioLogics announce strategic manufacturing tie-up for Tildrakizumab cphi-online
July 06, 2017
Tildrakizumab is an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis.
Sun Pharma signs $55m manufacturing deal for investigational psoriasis drug pharmafile
July 05, 2017
India’s biggest pharma firm has signed a $55 million long-term manufacturing deal with Korea’s Samsung BioLogics for Tildrakizumab, an investigational IL-23p19 inhibitor currently being assessed for efficacy in treating moderate to severe plaque psoriasis
Sun Pharma ties up with Samsung BioLogics financialexpress
July 05, 2017
Samsung BioLogics will manufacture Tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis
Sun Pharma ties up with Samsung BioLogics expressbpd
July 05, 2017
Samsung BioLogics will manufacture Tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis
Sun Pharma and NIV sign agreement to fight Zika, Chikungunya and dengue expressbpd
June 28, 2017
Sun Pharma will provide drug molecules to NIV for testing against Zika, Chikungunya and dengue in model systems
Pharma and NIV sign agreement to fight Zika, Chikungunya and dengue expressbpd
June 27, 2017
Pharma and NIV sign agreement to fight Zika, Chikungunya and dengue
Sun Pharma announces US FDA Filing acceptance of BLA pharmaasia
June 07, 2017
Tildrakizumab is being evaluated for treatment of moderate-to-severe plaque psoriasis.

Previous page 1 2 3 4 5 6 7 8 9 Next page